Indeed, clinical studies targeting BCLXL in glioblastoma multiforme (NCT00540722; http://clinicaltrials.gov/ct2/show/NCT00540722) and small cell lung cancer (NCT03080311; http://clinicaltrials.gov/ct2/show/NCT03080311) are ongoing; monotherapy has been conducted in these studies. Here, BCL2L1 is linked to small cell lung carcinoma.